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Microabstract 
Eligibility criteria for clinical trials are important for maintaining patient safety and 
scientifically valid results.    Patients are commonly excluded from trials due to a history of 
a previous cancer.    We demonstrate that patients with a previous cancer have similar 
survival to those who do not, and that this is not a justifiable reason to exclude them from 
clinical trial participation.  
 
Abstract 
Background:  
Strict eligibility criteria are necessary to maintain patient safety and scientific validity in 
clinical trials. However this may lead to impaired generalizability of results.  As survival in 
gastrointestinal (GI) cancer relates mainly to the GI malignancy, we hypothesised that 
previous cancers do not impact on survival and are not a rational exclusion criterion.  
 
Materials and Methods:  
Patients treated with chemotherapy for a GI cancer in 2006 were identified from the 
electronic patient record at the Royal Marsden, London.  Chart review was performed and 
patient age, gender, GI cancer stage, prior cancer stage, clinical trial availability/eligibility, 
and dates of cancer recurrence, death and last follow up were collated.  
 
Results:  
697 patients were identified. 54 patients (8%) had a prior cancer; commonly breast (26%), 
prostate (17%), or colon (9%); most were stage I (42%) or II (37%). 297 (65%) patients 
had GI cancer recurrence, 7 (12%) patients had relapse of a prior cancer. 504 (72%) 
patients have died, 170 (24%) are alive with no cancer and 23 (3%) patients are alive with 
cancer. 476 (94%) died of GI cancer, 2 (0.3%) of their prior cancer. 489 (70%) of all 
patients had an available trial but 30% of patients with a prior cancer were ineligible for 
this reason. Overall and GI cancer specific survival were comparable for patients 
with/without a prior cancer.  
 
Conclusions: 
Survival for patients with a GI cancer requiring chemotherapy relates to the GI cancer and 
rarely a prior cancer.  These patients should not be excluded from clinical trial 
participation. 
 
Clinical practice points 
What is already known about this subject? 
Exclusion of patients from clinical trials due to a previous cancer diagnosis is common 
however there is limited evidence to support this practice.     As rates of cancer survival 
increase and a large group of patients are excluded from clinical trial participation it is 
necessary to challenge this paradigm.  
What are the new findings? 
We demonstrate that for patients with a new diagnosis of a gastrointestinal cancer and a 
history of a previous cancer  that their survival relates to the current gastrointestinal 
cancer and not their previous malignancy.       Furthermore, one third of patients with a 
previous cancer were prevented from participating in a clinical trial due to their previous 
cancer.    
 How might it impact on clinical practice in the foreseeable future? 
We conclude that patients with a previous cancer which had been previously treated 
should not be excluded from clinical trial participation.    As survivorship issues become 
more prevalent it is important that these patients have just access to clinical trials.  Clinical 
trial generalizability is also improved by including patients reflective of the general 
population.  
Introduction 
 
Randomised clinical trials are the backbone upon which novel, increasingly effective 
therapies for cancer are based, and patient participation in randomised trials may lead to 
enhanced survival in particular in the short term.1, 2   However the relevance of any clinical 
trial relies heavily on external validity and trial generalizability may be significantly affected 
by factors such as exclusion criteria.3  Furthermore although results from clinical trials 
provide the empirical evidence used to treat patients rationally, patient accrual often falls 
short of expectations. This is demonstrated by a study of 114 Medical Research Council 
sponsored trials which revealed that less than one-third achieved their target enrolment 
within the specified timeframe.4   Such low accrual rates may lead to insufficient statistical 
power and early trial termination.  This represents a missed opportunity to answer a 
clinical and scientific question and a squandering of scant resources.   
 
In theory, stringent eligibility criteria are necessary for clinical trials in order to maintain the 
safety of the patient and the scientific value of the protocol. Many of these criteria are 
common to all clinical trials and along with “poor performance status” one of the most 
frequent of these is the exclusion of patients with any previous invasive cancer. 5, 6  As the 
population ages and treatments of early stage tumours improve the proportion of  patients 
with a prior history of cancer will inevitably increase – in 1971 there were 3 million cancer 
survivors in the United States, by 2007 this was 11.7 million.7  Excluding these patients 
may further decrease the pool of potential clinical trial participants and may limit the 
generalizability of trials which are performed. Although many suggestions have been 
made as to how to increase participation in clinical trials, the validity of this commonly 
used exclusion criteria has not been previously examined. 
 
 
As survival for patients with advanced gastrointestinal cancers (oesophagogastric (OGJ)], 
pancreatic, hepatocellular (HCC], cholangiocarcinoma and colorectal cancer) is more 
likely to be determined by that cancer that any previous cancer we hypothesised that 
previously treated, unrelated cancers are less likely to impact on survival than is 
suggested and that therefore a history of a previously treated cancer may not be rational 
reason to exclude patients from clinical trials in gastrointestinal malignancies.8-12    In this 
study, we examine the survival outcomes of patients with and without a prior cancer 
treated with chemotherapy in the GI Unit of the Royal Marsden Hospital over a one year 
period, and how a history of a previous cancer in a patient affected clinical trial eligibility 
during that timeframe. 
 
Materials and Methods 
For this retrospective observational study we collected data on patients with 
gastrointestinal cancer (colorectal, oesophagogastric, pancreatic, and hepatocellular 
cancer) who received treatment between 1st of January 2006 and 31st of December 2006 
at the Royal Marsden Hospital, London. Patient details were extracted from the electronic 
patient record. Eligibility criteria included age of 18 and over, diagnosis of colorectal, 
gastro-oesophageal, pancreatic, or hepatocellular cancer and treatment with 
chemotherapy in the year 2006. The following information was collected following chart 
review:  patient age, gender, gastrointestinal cancer stage, prior cancer tissue of origin 
and stage, clinical trial availability and eligibility, and dates of cancer recurrence, death, 
cause of death and last follow-up.   The electronic records of the Gastrointestinal Clinical 
Trials Unit were reviewed to identify the opening and closing dates of pertinent clinical 
trials for the period under review, and the relevant protocols were reviewed with respect to 
eligibility criteria.  
 
All non-trial patients in the Gastrointestinal Oncology Unit are followed according to 
departmental protocols.   Patients receiving active treatment for metastatic disease are 
followed as per chemotherapy protocol whilst receiving chemotherapy and three monthly 
whilst on treatment breaks.     Patients with resected neoadjuvantly or adjuvantly treated 
cancers are followed every three months for the first year, then six monthly for years two 
and three following resection, and then annually until year five when they are discharged.    
Patients with resected stage IV colorectal cancer are followed for seven years.  Survival 
outcomes are collected by hospital administrative staff from a national database.   
Patients participating in clinical trials were followed as per individual trial protocol.  
 
Overall survival (OS) was calculated from date of diagnosis of gastrointestinal cancer to 
date of death and gastrointestinal cancer specific survival (GCSS) was calculated from 
date of diagnosis of gastrointestinal cancer to date of death where cause of death was GI 
cancer (censored at date of death for other cause of death).  Survival estimates were 
calculated according to the Kaplan-Meier method, and are presented with 95% confidence 
intervals. Differences in survival between groups were compared with the log-rank test.  
All analysis was performed in SPSS version 22.  Multivariate Cox regression analysis was 
performed using the variables age, stage, and cancer subtype in order to assess the 
independent impact of these variables on gastric cancer specific and overall survival.  The 
study was reviewed and approved by the Institutional Review Board (SE61) and did not 
require patient consent, nor did it have any influence on patient management.   The year 
2006 was chosen to allow for adequate follow up of at least 5 years for surviving patients 
and mature assessment of survival data.  
 
Results  
Patient population  
A total of 697 patients were identified. Patient characteristics are presented in Table 1. 
The majority of patients were male (59%), median age was 62 years for all patients. The 
most commonly treated GI tumour type was colorectal cancer (74%). Fifty-four (8%) of 
patients had a previously treated cancer.   Breast, prostate and colon cancer together 
accounted for more than half of these previous cancers; almost 80% of previously treated 
cancers were Stage I or II.  The median time from diagnosis of a previous cancer until 
current diagnosis was 7.9 years.  Patients with a prior cancer were significantly older than 
patients without (median 61 years vs 67 years, p<0.001), but were similar in all other 
baseline characteristics.  
 
Of the 459 patients in the study with GI cancer that did not have metastatic cancer at 
presentation, 297 (65%) developed a recurrence of their GI cancer.  Of the 54 patients 
with a previously treated cancer 7 (12%) developed a recurrence of the previously treated 
cancer (however five of these recurrences had occurred prior to their GI cancer diagnosis 
and been treated successfully with curative intent).   Two patients had a recurrence of a 
previous cancer after their GI cancer diagnosis. These were one patient with a previous 
spinal cord glioma and a one patient with a history of resected bladder cancer, and both of 
these patients died of their recurrent original non-GI cancer.   To date, 504 (72%) patients 
have died, 170 (24%) are alive with no cancer and 23 (3%) patients remain alive with 
cancer. Among the deceased patients, their primary GI cancer was the cause of death in 
476 (94%) patients, followed by other reasons in 26 (5%) of patients and their prior cancer 
in 2 (<1%) patients.    
 
Impact of prior cancer on clinical trial recruitment 
  
Of the 697 patients who were treated in the referent time period, 489 (70%) patients had 
an available clinical trial at the time of gastrointestinal cancer treatment, and 113 (23% of 
patients with trial available, 16% of all patients) were enrolled into a clinical trial. Nine (2% 
of total) patients with a trial available were excluded because of a prior history of cancer. 
Of the 30 patients with prior cancer for whom a clinical trial was identified, nine of these 
(30%) patients were excluded due to their previous malignancy.  Thirteen patients were 
excluded from trial participation for other reasons; of the remainder who were trial 
eligible with an available trial (n=8)  55% chose to participate in a clinical study.     
Both gastrointestinal cancer specific survival and overall survival were comparable 
between patients who participated and who did not participate in clinical trials.  These 
were 35.4 months (95% CI 25.4 – 45.5 months) versus 41.5 months (95% CI 34.0 – 49.0 
months), HR 1.06 (95% CI 0.82 – 1.37), p= 0.662 for gastrointestinal cancer specific 
survival and 35.4 months (95% CI 25.4 – 45.5  months)  versus 40.0 months (95% CU 
32.8 – 47.2 months), HR 1.00 (95% CI 0.78 – 1.29), p=0.991 for median overall survival 
respectively.   
 
Impact of prior cancer on survival 
 
Median follow-up time was 83.2 months (95% Cl: 77.9 – 88.5 months). Median 
gastrointestinal cancer specific survival (GCSS) was 41.4 months (95% CI: 36.7 – 46.1) 
for all patients.  This (GCSS) was 41.2 months (95% CI: 36.1-46.3) for patients with no 
history of a previous cancer versus 47.4 months (95% CI: 32.8-62.0) for prior cancer 
patients (p=0.75) (Fig 1).   Median overall survival (OS) for all patients was 40.6 months 
(95% CI: 36.1 - 45.0).  This was 40.6 months (95% CI: 36.1-45.1) for patients with no prior 
cancer patients versus 37.4 months (95% CI: 20.7-54.0) for patients who did have a prior 
cancer, these were not significantly different (p= 0.42) (Fig 2).  Survival was comparable 
for patients with curatively resected cancer (Stage I-III) and for patients with advanced 
disease (Stage IV) whether or not they had a prior cancer (p=0.375 and  0.712 for 
interaction between stage and OS and DSS respectively).    Multivariate analysis 
demonstrated  that whereas for both DSS and OS age, stage and non-colorectal cancer 
histology were independently associated with survival, a history of a previous cancer was 
not  (Table 2).   
 
Discussion  
Stringent eligibility criteria in clinical trials may be justified to ensure  
patient safety and the scientific value of the protocol.  However, this objective may impair 
generalizability of trial results as many patients are excluded due to common 
comorbidities; most frequently for kidney, infectious, cardiac, liver or haematological-
oncological disease which may not impact on the research hypothesis in question.5  In our 
study we provide evidence that for patients with common gastrointestinal malignancies a 
prior history of a treated cancer does not result in inferior survival when compared with 
those patients without a previous malignancy. 
 
Factors other than a history of a previous malignancy may influence the survival of cancer 
patients, and in order to address the potential confounders of age, stage and histological 
subtype within our study we have performed multivariate analysis using these factors as 
variables.   Unsurprisingly, age, the presence of metastatic disease and non-colorectal 
cancer histology were independent predictors of survival.    There are clear differences in 
the survival of gastrointestinal cancers based on tissue of origin and stage.  For example, 
median survival in clinical trials for patients with metastatic pancreatic cancer is less than 
one year and for these patients it is unlikely that a previous cancer poses a significant 
competing risk for death.     Alternatively, for patients with less biologically aggressive 
metastatic cancers such as colorectal cancer a previous cancer may represent a more 
frequent cause of death.    However regardless of cancer subtype tumour stage remains 
the strongest predictor of survival in our analysis and it may be possible to argue that for 
all patients with advanced or metastatic incurable cancer that a history of a prior 
malignancy is unlikely to be relevant with respect to survival.      
 
In our study, age was also incrementally but independently associated with reduced 
survival.    As patients in our study with a second cancer had a mean age six years older 
than those without a similar history, it is possible that this is the reason that the univariate 
Kaplan-Meier overall survival curve appears to diverge for patients with and without a 
previous cancer (we acknowledge that although this difference is non-significant the 
analysis may be underpowered).    However, despite the fact that increasing age predicts 
for worse survival, there is strong support for the enrolment of older patients in clinical 
trials in order to increase the representativeness of clinical trial populations.13    In contrast 
with increasing age,   that a previous cancer does not appear to adversely affect survival 
provides further support for our argument against exclusion of these patients.  
 
We note that in our study, the median time from a previous cancer diagnosis was almost 
eight years, which raises the question of whether the lead time from previous cancer 
impacts on the chances of recurrence.   The low absolute numbers of patients in our study 
with a previous cancer make it difficult to form any meaningful observations in this regard, 
however we appreciate the point at which a patient may be considered “cured” of a cancer 
is variable –indolent hormone sensitive breast cancer or lymphomas may recur after a 
period of decades whereas late (> five years) recurrences of more aggressive epithelial 
cancers are rare.   This clearly adds to the complexity of any proposal for including 
patients with prior cancers in clinical trials, but does not necessarily render the problem 
unsolvable.    Due to the exponentially decreased risk of recurrence for most high grade 
cancers after three years this would seem a very reasonable timeframe to suggest as a 
cancer free baseline.    
 
In this study population the percentage of patients with a prior cancer was 7.7%, a 
proportion which likely reflects the gastrointestinal cancer population studied (as second 
malignancies may be more common in other populations).  It has been previously 
documented that patients with breast, prostate and colon cancer are at significantly 
increased risk of second malignancies, and these patients represented the majority of 
patients in our study.14-16  Rates of early diagnosis and cure of these cancers are high, 
and may continue to increment with implementation of more comprehensive screening 
programmes and increasing efficacy of treatment for early stage disease.17-19   In the 
United States, the number of cancer survivors is increasing by 2% per annum and 
according to SEER data as many as 18% of US cancers may be a second or subsequent 
malignancy.20  A recent study supports our argument – Gerber et al demonstrated that up 
to 80% of US ECOG sponsored or endorsed lung cancer trials excluded patients with a 
prior malignancy and that his affected up to 18% of lung cancer patients.21  The same 
group have also recently demonstrated that both lung cancer specific survival and overall 
survival for lung cancer patients with a history of a prior cancer was not inferior to those 
without, thus supporting our hypothesis in another cancer group.22 Our study 
demonstrated that 2% of the total population were potentially denied participation in a 
clinical trial as a result of a previous cancer.   Although this is a small proportion of the 
total compared to the previously mentioned study it may be reflective of the patient make 
up of our dataset who were predominantly patients with colorectal cancer which has a 
weaker link to environmental exposures such as tobacco.   For example, 10% of patients 
in our study with gastroesophageal cancer had a history of a previous cancer, possibly 
reflecting a stronger link in this group to underlying alcohol and smoking aetiologies.   
However, even if the figure of 2% is prevented from trial participation, we believe that this 
is unwarranted and unjust in principle.  This is a significant proportion of patients to 
exclude from any clinical trial especially given the lack of rationale for this evidenced in 
our study, and in particular from randomised trials where any effect (if one existed) would 
be nullified by randomisation.  Furthermore, when considering cancer survivors as a 
group, 30% of these patients were prevented from participating in trials as a result of their 
previous cancer.  Furthermore, when a trial was available and this group was 
eligible, more than half of patients chose to participate.     As advocacy groups for 
cancer survivors become increasingly involved in peer review of research strategies and 
funding,  this inequity must surely be questioned.23 
 
Limitations of our study include its retrospective nature and the inclusion of patients with 
differing cancer histologies.   However, this is reflective of the patients treated at our 
cancer centre, and we believe that it is generalisable to a wider population.  We note that 
the survival of patient who did and did not participate in trials during this period was not 
different, which supports the external validity of these results.    We chose one specific 
year (2006) in order to ascertain sufficient follow up of patients to detect potential 
recurrences and also to provide a finite timescale in which to examine the trials which 
were on offer at that time.   We acknowledge that our analysis could be 
underpowered despite containing almost 700 patients as the proportion of patients 
with a prior cancer diagnosis is low and thus one might interpret any non-significant p 
values with caution. However in performing multivariate analysis we have attempted to 
demonstrate as robustly as possible within the dataset available that expected 
confounders of age, stage, histological subtype are independently associated with survival 
and that a history of a previous cancer is not.   Although expanding the time scale would 
provide us with greater power to examine each individual histology, doing this 
retrospectively would prove difficult due to a lack of previous electronic records, and 
prospective observational studies would require significant follow up and may not provide 
additional information.     Our study was conducted at a comprehensive cancer centre and 
this is evident in the high proportion of patients for whom a clinical trial was available 
(70%) and who participated in a trial (16% of total).   Although this could potentially 
introduce a bias in survival times, this should apply equally to all patients as this is a 
single centre study.   The number of patients with a previous cancer is consistent with the 
literature, and does not appear to have been influenced by the nature of the institution, 
however this may not be true of all cancers.24  
 
In the UK, participation in clinical research is amongst the highest in developed countries, 
however the aspiration is for all patients to be offered the opportunity to participate in 
clinical research should they so wish, and are eligible.  Governments worldwide include 
reducing barriers to participation in trials as a stated goal. 25 26  However, in order to 
improve on current recruitment rates to cancer clinical trials it may be necessary to 
question the validity of commonly held beliefs regarding eligibility.    Just as older patients 
should not be excluded by virtue of their age alone, we argue that neither should patients 
with a history of an adequately treated previous cancer.27, 28   As significant health and 
socio-economic inequalities have previously been identified for cancer survivors to 
remedy this one by providing equal access to clinical trials seems both sensible and fair.29-
31 
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Table 1:  Baseline characteristics 
 No Prior Cancer Prior Cancer P-value 
 N % N % 
Gender  
 Male 
 Female 
 
383 
260 
 
59.6 
40.4 
 
26 
28 
 
48.1 
51.9 
 
0.102 
Age (mean) 61  67  <0.001 
Diagnosis of Primary 
 CRC 
 EGC 
 HCC 
 Pancreatic  
 
471 
60 
27 
85 
 
73.3 
9.3 
4.2 
13.2 
 
42 
6 
1 
5 
 
77.8 
11.1 
1.9 
9.3 
 
0.661 
Stage of Primary 
 I 
 II 
 III 
 IV 
 
19 
110 
268 
246 
 
3.0 
17.1 
41.7 
38.3 
 
3 
12 
18 
21 
 
5.6 
22.2 
33.3 
38.9 
 
0.447 
Prior Malignancy 
 Yes  
 
0 
 
0 
 
54 
 
100 
 
Site of Prior Malignancy 
 Breast 
 Colon 
 Cervix 
 Bladder 
 Melanoma 
 Prostate 
 Lymphoma 
 Ovarian 
 Other 
   
14 
5 
3 
2 
3 
9 
2 
2 
14 
 
25.9 
9.3 
5.6 
3.7 
5.6 
16.7 
3.7 
3.7 
25.9 
 
Stage of Prior Malignancy  
 I 
 II 
 III 
 IV 
   
23 
20 
10 
1 
 
42.6 
37.0 
18.5 
1.9 
 
Abbreviations:  CRC, colorectal cancer; EGC, esophagogastric cancer; HCC, hepatocellular carcinoma 
 
 Table 2: Gastrointestinal Cancer Survival Multivariate Analysis 
 Hazard Ratio 95 % CI p-value 
Prior Cancer 1.01 0.72 – 1.40  
Age  1.02 1.01 – 1.03 <0.001 
Non CRC type 2.46 2.02 – 2.99 <0.001 
Stage IV 2.98 2.48 – 3.59 <0.001 
 
 
 
 
 
 
Table 3:  Overall Survival Multivariate Analysis 
 Hazard Ratio 95 % CI p-value 
Prior Cancer 1.07 0.78 – 1.46 0.676 
Age  1.02 1.01 – 1.03 <0.001 
Non CRC type 2.40 1.98 – 2.92 <0.001 
Stage IV 2.74 2.30 – 3.28 <0.001 
 
 
 
